Cargando…
Management of Hypertension Using Olmesartan Alone or in Combination
Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hyper...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446820/ https://www.ncbi.nlm.nih.gov/pubmed/28258390 http://dx.doi.org/10.1007/s40119-017-0087-5 |
_version_ | 1783239172667998208 |
---|---|
author | Zhang, Xiaoshen Zhang, Han Ma, Yuxia Che, Wenliang Hamblin, Michael R. |
author_facet | Zhang, Xiaoshen Zhang, Han Ma, Yuxia Che, Wenliang Hamblin, Michael R. |
author_sort | Zhang, Xiaoshen |
collection | PubMed |
description | Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients. |
format | Online Article Text |
id | pubmed-5446820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-54468202017-06-13 Management of Hypertension Using Olmesartan Alone or in Combination Zhang, Xiaoshen Zhang, Han Ma, Yuxia Che, Wenliang Hamblin, Michael R. Cardiol Ther Review Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients. Springer Healthcare 2017-03-03 2017-06 /pmc/articles/PMC5446820/ /pubmed/28258390 http://dx.doi.org/10.1007/s40119-017-0087-5 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Zhang, Xiaoshen Zhang, Han Ma, Yuxia Che, Wenliang Hamblin, Michael R. Management of Hypertension Using Olmesartan Alone or in Combination |
title | Management of Hypertension Using Olmesartan Alone or in Combination |
title_full | Management of Hypertension Using Olmesartan Alone or in Combination |
title_fullStr | Management of Hypertension Using Olmesartan Alone or in Combination |
title_full_unstemmed | Management of Hypertension Using Olmesartan Alone or in Combination |
title_short | Management of Hypertension Using Olmesartan Alone or in Combination |
title_sort | management of hypertension using olmesartan alone or in combination |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446820/ https://www.ncbi.nlm.nih.gov/pubmed/28258390 http://dx.doi.org/10.1007/s40119-017-0087-5 |
work_keys_str_mv | AT zhangxiaoshen managementofhypertensionusingolmesartanaloneorincombination AT zhanghan managementofhypertensionusingolmesartanaloneorincombination AT mayuxia managementofhypertensionusingolmesartanaloneorincombination AT chewenliang managementofhypertensionusingolmesartanaloneorincombination AT hamblinmichaelr managementofhypertensionusingolmesartanaloneorincombination |